{"nctId":"NCT00739674","briefTitle":"SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)","startDateStruct":{"date":"2008-02-01","type":"ACTUAL"},"conditions":["Hypertension"],"count":992,"armGroups":[{"label":"Losartan-Based Regimen Alone (L Group)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])"]},{"label":"Diet Management and Losartan-Based Regimen (DML Group)","type":"EXPERIMENTAL","interventionNames":["Drug: losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])","Behavioral: Low Salt Diet"]}],"interventions":[{"name":"losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])","otherNames":[]},{"name":"Low Salt Diet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non Diabetic, Newly Diagnosed And Untreated For Mild To Moderate Hypertension (blood pressure \\> 161; \\< 221; 140/90 mm Hg But \\< 180/110 mm Hg)\n* Non diabetic, newly diagnosed and untreated for severe hypertension (blood pressure \\> 180/110 mm Hg but \\< 200/120 mm Hg); Patients who are asymptomatic with no evidence of significant end organ damage including direct pressure effects can be included. Patients in an urgency/emergency state are to be excluded\n* Or Diabetic, Newly Diagnosed With Hypertension And Untreated With Mild To Moderate Hypertension (blood pressure \\> 161;\\< 221; 130/80 mm Hg But \\< 160/100 mm Hg); Or Patient Receiving One Antihypertensive Agent (Monotherapy Only) Used To Treat Hypertension For At Least 4 Weeks And Whose Blood Pressure Is Not Controlled: blood pressure \\> 161;\\< 221; 140/90 mm Hg But \\< 160/100 mm Hg Or For Diabetic And/Or Coronary Artery Disease Patients: blood pressure \\> 161;\\< 221; 130/80 mm Hg But \\> 161;\\< 221; 150/90 mm Hg\n* The Antihypertensive Agent Will Need To Be Discontinued Prior To Starting Study Drug\n\nExclusion Criteria:\n\n* Known Secondary Hypertension Of Any Aetiology (E.G., Uncorrected Renal Artery Stenosis, Malignant Hypertension, Hypertensive Encephalopathy. Patient With Symptomatic Heart Failure (Classes 3 And 4). Patient With A Prior Myocardial Infarction Or Stroke Within The Last 6 Months\n* Patient Has Undergone Percutaneous Coronary Angioplasty, Has Had Coronary Artery Bypass Within The Last 6 Months Or Has Unstable Angina\n* Patient With Anuria Or Confirmed Clinically Significant Renal Or Hepatic Dysfunction (Taken From Current/Past Medical Records) And/Or Electrolyte Imbalance Laboratory Test Within The Last 3 Months Prior To Visit 1: Serum Creatinine \\> 130 ÃŒmol/L Or Creatinine Clearance \\< 45 Ml/Min, Ast \\> 3 Times Above The Normal Range, Alt \\> 3 Times Above The Normal Range, Serum Potassium \\< 3.5 Or \\> 5.5 Meq/L\n* Significant Liver Or Respiratory Disease, Cancer Or Other concomitant Disease That Is Likely To Affect Life Expectancy Of The Patient","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline","description":"Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 14 weeks of treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"276","spread":null},{"groupId":"OG001","value":"270","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Achieving Target Blood Pressure at Week 6 From Baseline","description":"Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 6 weeks of treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"231","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Achieving Target Blood Pressure at Week 10 From Baseline","description":"Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 10 weeks of treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"257","spread":null},{"groupId":"OG001","value":"254","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Achieving Target Blood Pressure at Week 40 From Baseline","description":"Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 40 weeks of treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"264","spread":null},{"groupId":"OG001","value":"240","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Systolic Blood Pressure From Baseline to Week 14","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.01","spread":"14.11"},{"groupId":"OG001","value":"-22.74","spread":"15.81"}]}]}]},{"type":"PRIMARY","title":"Change in Diastolic Blood Pressure From Baseline to Week 14","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.19","spread":"9.33"},{"groupId":"OG001","value":"-12.05","spread":"9.50"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure From Baseline to Week 6","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.81","spread":"14.92"},{"groupId":"OG001","value":"-18.85","spread":"16.18"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure From Baseline to Week 6","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.34","spread":"9.29"},{"groupId":"OG001","value":"-9.76","spread":"9.82"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure From Baseline to Week 10","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.11","spread":"14.87"},{"groupId":"OG001","value":"-20.95","spread":"16.24"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure From Baseline to Week 10","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.48","spread":"8.80"},{"groupId":"OG001","value":"-11.42","spread":"9.45"}]}]}]},{"type":"SECONDARY","title":"Time to Achieve the Target Blood Pressure From Baseline","description":"Time to achieve the target blood pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.43","spread":null},{"groupId":"OG001","value":"6.57","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":531},"commonTop":["Dizziness","Headache","Hypotension","Fatigue","Diarrhoea"]}}}